Trade Names:Kantrex- Capsules 500 mg- Injection 500 mg- Injection 1 g- Pediatric Injection 75 mg
Inhibits production of bacterial protein, causing cell death.
Rapidly absorbed after IM injection. T max is approximately 1 h. C max is 22 mcg/mL (from the 7.5 mg/kg dose). Poorly absorbed from the normal GI tract (orally).
Diffuses rapidly into most body fluids including synovial and peritoneal fluids and bile. Significant levels of drug appear in cord blood and amniotic fluid.
Little if any metabolic transformation occurs.
Plasma t ½ is 2 h.
Excreted almost entirely by glomerular filtration and is not reabsorbed by the renal tubules. Renal excretion is extremely rapid. The unabsorbed portion is eliminated unchanged in the feces.
48 to 72 h
Patients with renal function impairment or diminished glomerular pressure excrete kanamycin more slowly. May build up excessively high blood levels that lead to increased risk of ototoxic reactions.Severely burned patients
In severely burned patients, t ½ may significantly decrease. As result serum concentrations may be lower.
Short-term treatment of serious infections caused by susceptible strains of microorganisms, especially gram-negative bacteria.Oral
Short-term adjunctive therapy for suppression of intestinal bacteria; treatment of hepatic coma.
Hypersensitivity to aminoglycosides; intestinal obstruction (oral). Generally not indicated for long-term therapy (more than 14 days) because of ototoxicity and nephrotoxicity.
IM/IV 15 mg/kg/day in 2 to 4 divided doses. Do not exceed 1.5 g/day.Suppression of Intestinal BacteriaAdults
PO 1 g every hour for 4 h, then 1 g every 6 h for 36 to 72 h.TuberculosisAdults and children
IM/IV 15 to 30 mg/kg/day (max, 1 g/day).Hepatic ComaAdults
PO 8 to 12 g/day in divided doses.
Store at room temperature. Darkening of vials during shelf life does not indicate loss of potency.
Do not mix in IV solutions.Digoxin, methotrexate, vitamin A, vitamin K
Oral kanamycin may decrease absorption of these drugs.Drugs with nephrotoxic potential (eg, amphotericin, cephalosporins, enflurane, methoxyflurane, vancomycin)
Increased risk of nephrotoxicity.Loop diuretics
Increased auditory toxicity.Neuromuscular blocking agents
Enhanced effects of these agents.Polypeptide antibiotics
Increased risk of respiratory paralysis and renal function impairment.
None well documented.
Hearing loss; deafness; loss of balance.
Malabsorption syndrome (eg, increased fecal fat, decreased serum carotene, fall in xylose absorption); nausea; vomiting; diarrhea.
Oliguria; proteinuria; elevated serum creatinine and BUN; granular casts; red and white cells in urine; decreased CrCl.
Pain and irritation at injection site; acute muscular paralysis; hypomagnesemia.
Manifests as both auditory and vestibular ototoxicity, and primarily occurs in patients with preexisting renal damage with prolonged therapy. Partial or total irreversible deafness may continue to develop after drug is stopped. Other features of neurotoxicity include paresthesia, twitching, and seizures.Nephrotoxicity
Teratogenic in pregnancy.
Closely monitor renal and eighth nerve function in patients with suspected renal function impairment. Monitor peak and trough concentrations. Dosage adjustments are required in renal function impairment.
Category D .
Excreted in breast milk.
Use cautiously in premature infants and newborns because of renal immaturity.
Use with caution in patients with neuromuscular disorders, those receiving anesthesia or muscle relaxants, hypomagnesemia, hypocalcemia, hypokalemia, or in newborns whose mothers received magnesium sulfate.
Increased absorption (and potential for toxicity) when intestinal mucosa is ulcerated or denuded.
Nephrotoxicity, auditory toxicity, vestibular toxicity, neuromuscular blockade, respiratory paralysis.
Copyright © 2009 Wolters Kluwer Health.